Key result
GLP-1 RAs, gut hormones, and non-steroidal MRAs show evolving cardiorenal benefits in diabesity and CKD.
Why the study?
The pandemics of obesity and T2DM are increasing the prevalence of CKD, while treatment options have rapidly expanded and questions remain regarding the timing and sequencing of multitarget therapy.
This commentary outlines the evolving paradigm of multitarget renoprotective and cardioprotective therapy in patients with obesity, T2DM, and CKD.
Answers are grounded in this paper and cite their sources.
May support multitarget therapy exploration in diabesity-CKD; leaves open confirmation by dedicated RCTs.
The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD). Treatment options for such patients have rapidly expanded over the past decade and continue to evolve. Herein, we primarily focus on glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their role in the management of CKD in the setting of overweight/obesity and T2DM. Recommendations from the recent Kidney Disease: Improving Global Outcomes CKD guidelines are summarized and new evidence arising since publication of these guidelines is highlighted. We review clinical studies supporting the role of GLP-1RAs in patients with diabesity and CKD, including the FLOW trial, as well as exploring potential mechanisms of their nephroprotective effects. Their role in the management of patients with ESKD on maintenance dialysis and after kidney transplantation, while less evidence-based, is also discussed. The potential for other gut hormone-based therapies, including GLP-1/glucose-dependent insulinotropic polypeptide dual agonists (tirzepatide), triple agonists (incorporating glucagon agonism) and amylin analogues to improve cardiovascular and kidney outcomes in patients with CKD, is explored. We highlight the role of novel therapies distinct from the gut-kidney axis, including non-steroidal mineralocorticoid receptor antagonists (nsMRAs). We outline the potential for multitarget therapy incorporating renin-angiotensin-aldosterone system inhibitors, sodium-glucose co-transporter-2 inhibitors, incretin-based treatments and nsMRAs to improve cardiovascular and kidney outcomes in patients with overweight/obesity and T2DM. Current unknowns in the timing and sequence of multitarget therapy in patients with CKD are emphasized. Priority research questions for the future are highlighted throughout the review.
No takes yet. Share an insight, caveat, or question.
Morales et al. (2025) conducted a review in Chronic kidney disease with obesity and type 2 diabetes mellitus. GLP-1 receptor agonists, novel gut hormone-based therapies, and nsMRAs was evaluated. This review outlines the evolving role of GLP-1 receptor agonists, novel gut hormone-based therapies, and non-steroidal MRAs for improving cardiovascular and kidney outcomes in diabesity and CKD.
Synapse has enriched 10 related papers. Consider them for comparative context: